OpenAI 收购 Orchestra Bio,并入生命科学品牌 Rosalind
OpenAI 于 2026 年 10 月 20 日宣布收购 Orchestra Bio,后者的药物研发协调平台及团队将并入 OpenAI 的生命科学品牌 Rosalind。Orchestra Bio 的平台让科学家把研究进展的监控与追踪交给智能体,由智能体定位受影响的环节和时间线并比较应对方案。Rosalind Workbench 目前处于研究预览阶段,提供 Explore 和 Research 两种模式,GPT-Rosalind 也可在 Codex 中使用,API 需通过资格审核。
ts make discoveries and manage the work required to turn those discoveries into treatments that reach patients sooner. Developing a new medicine takes roughly 10 to 15 years on average from target discovery through regulatory approval in the United States, according to the company, and the teams behind those programs must coordinate work across internal departments and external partners, often through disconnected systems. OpenAI describes the present moment as an inflection point at which AI ca
匹配字段正文
